Business Wire

New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groups

Share

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced additional results from prespecified subgroup analyses of the Phase 3 CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes trial. The results, presented at the 92nd European Atherosclerosis Society (EAS) Congress 2024, add to the growing understanding of the efficacy of NILEMDO®▼ (bempedoic acid) for the reduction of cardiovascular (CV) risk among patients at high-risk of CV disease. Specifically, results were presented for the subgroups of patients with obesity*, with metabolic syndrome (MetS)**, and female patients.1-6

LDL-C reduction in obese patients

Among patients with obesity in the CLEAR Outcomes trial, bempedoic acid reduced low-density lipoprotein cholesterol (LDL-C) levelsby 22.5% and MACE-4 by 23% versus placebo, and was well-tolerated with a similar safety profile as reported in the overall CLEAR Outcomes population.1 This increased efficacy regarding MACE-4 compared to the overall CLEAR Outcomes population is likely due to the higher underlying risk of CV events in this patient group.1 This data was previously presented at the ACC conference in April 2024.

LDL-C reduction in patients with or without MetS

In the CLEAR Outcomes subgroup analysis of patients with or without MetS, treatment with bempedoic acid reduced the risk of MACE-4 to a similar extent. This demonstrates bempedoic acid’s suitability as an option for patients requiring lipid-lowering therapy irrespective of their MetS status.2 Furthermore, results showed a small but significant reduction in body weight for patients with MetS.2 Bempedoic acid did not lead to an increase in new-onset diabetes in patients with or without MetS.2 The safety profile was generally comparable between MetS status and treatment group, however, higher rates of hyperuricemia were observed in patients with MetS randomised to bempedoic acid.2

Similar efficacy and safety profile across genders

CV outcomes data in women are scarce. In the CLEAR Outcomes trial, 48% of participants were female (6,740/13,970), achieving a near-equal gender balance.3 In this prespecified subgroup analysis, results showed that bempedoic acid demonstrated similar efficacy in CV risk reduction, versus placebo, in both male and female patients.3 Furthermore, the overall incidence of adverse events did not differ meaningfully between male and female patients.3 This data was previously presented at the ACC conference in April 2024.

Data from these subgroup analyses are consistent with results from the main CLEAR Outcomes analysis, which showed a 13% reduction in the relative risk of major adverse cardiovascular events defined as a four-component composite of death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke or coronary revascularisation (MACE-4).7 Furthermore, the safety profile in all patient subgroups was in line with that of the overall trial population.1-6

“Both men and women with obesity and/or metabolic syndrome are at significant risk of future cardiovascular events. The results presented at the EAS Congress suggest that bempedoic acid isan effective treatment for a range of patient subgroups.” saidIoanna Gouni-Berthold, University of Cologne, Center for Endocrinology, Diabetes, and Preventive Medicine. “As clinicians, our priority is to reduce LDL-C levels to lower the risk of CV events. Combination therapy with bempedoic acid may be one way to address this issue.”

“Our goal at Daiichi Sankyo is to help protect people from cardiovascular disease. To achieve this, we are working to improve the understanding of CV risk among a range of patient subgroups – including female patients who have previously been underrepresented in clinical trials. The data presented today adds to the growing body of evidence that bempedoic acid can be used effectively to address and manage the CV risk of patients who typically present to doctors,” said Stefan Seyfried, Vice President Medical Affairs, Specialty Medicines, at Daiichi Sankyo Europe GmbH.

Results of the CLEAR Outcomes subgroup analyses were presented as two ePoster sessions and four posters at the EAS Congress 2024:

  • ePoster session: Bempedoic acid for prevention of cardiovascular events in patients with obesity: A CLEAR Outcomes subset analysis, by S Nicholls, et al.1
  • ePoster session: Bempedoic acid efficacy and safety in 7,597 non-diabetic patients, with and without metabolic syndrome, from the randomized, placebo-controlled CLEAR Outcomes Trial, by P Taub, et al.2
  • Poster: Characteristics and outcomes for statin-intolerant women receiving bempedoic acid in the CLEAR Outcomes trial, by L Cho, et al.3
  • Poster: Identification and characterisation of patients with statin intolerance in France, by F Schiele, et al.4
  • Poster: Lipid-lowering therapy use and LDL-C goal attainment in France: Results from 1-year follow-up of the European observational SANTORINI study, by R Allouche, et al.5
  • Poster: Simulation of ezetimibe and bempedoic acid effect on LDL-C goal attainment in statin-intolerant patients across Europe: the 1-year follow-up SANTORINI observational study, by M Farnier, et al.6

*Obesity defined as BMI ≥30 kg/m2

**Metabolic syndrome defined as the presence of 1 or more of the following criteria: triglycerides ≥150mg/dL; HDL-C <40mg/dL for men or <50mg/dL for women; history of hypertension or blood pressure ≥130/85mmHG; fasting plasma glucose ≥100mg/dL; body mass index (used as a proxy for waist circumference) >25kg/m2 and >30kg/m2 for Asian and non-Asian patents, respectively.

About bempedoic acid and its fixed-dose combination with ezetimibe

Bempedoic acid is a first-in-class, oral, once-daily treatment to lower cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.8,9 Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.10

Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to statin or other LDL-C-lowering therapies.11 Bempedoic acid is not activated in skeletal muscle.10

Bempedoic acid is indicated in adults with established or at high risk for atherosclerotic CV disease to reduce CV risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:8,12

  • in patients on a maximum tolerated dose of statin with or without ezetimibe or,8,12
  • alone or in combination with ezetimibe in patients who are statin-intolerant, or for whom a statin in contraindicated.8,12

Bempedoic acid is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:8,12

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a or,8,12
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.8,12

The fixed-dose combination NUSTENDI® combines two complementary ways of reducing cholesterol in a once-daily tablet. NUSTENDI® is a fixed-dose combination (FDC) tablet containing bempedoic acid (the active pharmaceutical ingredient in NILEMDO®) and ezetimibe.

Bempedoic acid / ezetimibe FDC is indicated in adults with established or at high risk for atherosclerotic CV disease to reduce CV risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:12,13

  • in patients on a maximum tolerated dose of statin and not adequately controlled with additional ezetimibe treatment or,12,13
  • in patients who are either statin-intolerant, or for whom a statin in contraindicated, and not adequately controlled with additional ezetimibe treatment or,12,13
  • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets12,13

Bempedoic acid / ezetimibe FDC is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:12,13

  • in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe,12,13
  • alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,12,13
  • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin.12,13

Daiichi Sankyo Europe has licensed exclusive commercialisation rights to bempedoic acid and its FDC with ezetimibe (marketed as NILEMDO®and NUSTENDI®) in the European Economic Area, UK, Turkey and Switzerland from Esperion and is the full Marketing Authorisation Holder in these territories.

About CLEAR Outcomes trial

The CLEAR Outcomes trial was a Phase 3, event-driven, randomised, multicentre, double-blind, placebo-controlled trial.14 It was designed to evaluate whether treatment with bempedoic acid, marketed as NILEMDO®▼ in Europe, reduced the risk of cardiovascular events in a mixed population of patients who had or were at high-risk for CVD, and for whom primary or secondary CVD prevention was clinically indicated but who were unable or unwilling to receive statin treatment.14

The trial, which was fully enrolled in August 2019, randomised 13,970 patients, aged 18–85 years of age with an average age of 65.5 years at 1,250 sites in 32 countries across the world including 485 sites in Europe.14 Patients had a mean LDL-C at baseline of 3.59 mmol/L (139.0 mg per decilitre) and were randomised to either treatment with bempedoic acid 180 mg daily or matching placebo on a background of guideline-directed medical therapy in both the bempedoic acid and placebo groups.7 Patients were followed up for a median duration of 40.6 months.7

The primary endpoint of the CLEAR Outcomes trial was a four-component composite of major adverse CV events (MACE-4) defined as death from CV causes, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularisation.14 Key secondary endpoints included: MACE-3, a composite of three major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke); fatal and nonfatal myocardial infarction; coronary revascularisation; fatal and non-fatal stroke; cardiovascular death; and all-cause mortality.14

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need.

For more information, please visit www.daiichisankyo.com

This medicinal product is subject to additional monitoring.

References

________________________
1 EAS 2024 ePoster. Bempedoic acid for prevention of cardiovascular events in patients with obesity: A CLEAR Outcomes subset analysis, by S Nicholls, et al.
2 EAS 2024 ePoster. Bempedoic acid efficacy and safety in 7,597 non-diabetic patients, with and without metabolic syndrome, from the randomized, placebo-controlled CLEAR Outcomes Trial, by P Taub, et al.
3 EAS 2024 Poster. Characteristics and outcomes for statin-intolerant women receiving bempedoic acid in the CLEAR Outcomes trial, by L Cho, et al.
4 EAS 2024 Poster. Identification and characterisation of patients with statin intolerance in France, by F Schiele, et al.
5 EAS 2024 Poster. Lipid-lowering therapy use and LDL-C goal attainment in France: Results from 1-year follow-up of the European observational SANTORINI study, by R Allouche, et al.
6 EAS 2024 Poster. Simulation of ezetimibe and bempedoic acid effect on LDL-C goal attainment in statin-intolerant patients across Europe: the 1-year follow-up SANTORINI observational study, by M Farnier, et al.
7 Nissen, S.E., et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023. 13;388;(15): 1353–1364.
8 European Medicines Agency. Nilemdo - opinion on variation to marketing authorisation. Available at: https://www.ema.europa.eu/en/medicines/human/variation/nilemdo. Last accessed May 2024.
9 The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020. 41;(1): 111–188.
10 European Medicines Agency. NilemdoSummary of Product Characteristics. May 2024. Available at: https://www.ema.europa.eu/en/documents/product-information/nilemdo-epar-product-information_en.pdf. Last accessed May 2024
11 Pinkosky, S.L., et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016. 7: 13457.
12 Daiichi Sankyo Europe GMBH. First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk. Available at: https://www.businesswire.com/news/home/20240514593487/en/First-in-class-cholesterol-lowering-treatment-NILEMDO%C2%AE%E2%96%BC-and-its-combination-with-ezetimibe-NUSTENDI%C2%AE%E2%96%BC-approved-in-Europe-to-lower-LDL-cholesterol-and-reduce-cardiovascular-risk. Last accessed May 2024
13 European Medicines Agency. Nustendi - opinion on variation to marketing authorisation. Available at: https://www.ema.europa.eu/en/medicines/human/variation/nustendi. Last accessed May 2024.
14 Nicholls, S.J., et.al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021. 235: 104–112.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Gillian D’Souza
Daiichi Sankyo Europe GmbH
Senior Manager, Public Relations, Specialty Medicines
+49 1515 5195599

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Innovative Grid Boosting Technologies Needed to Bring Europe’s Decarbonisation Targets Within Reach, Says New Industry Report20.6.2024 09:00:00 CEST | Press release

CurrENT Europe, the industry association for European innovative grid technology companies, and economic consulting firm Compass Lexecon are releasing a new innovative grid technologies report. Grids are increasingly becoming a bottleneck. Up until now, the transition has been focused on the production side of clean energy generation, but we are now hitting the limits of our grid. The energy transition urgently needs more grid capacity. Electrical transmission and distribution network lengths across Europe need to grow by up to 50% and 60% respectively if we are to see a fully decarbonized power system by 2040. Innovative Grid Technologies (IGTs) can improve grid capacity up to 40%, generating between 100-200GW of extra capacity by 2040. Even a conservative deployment of innovative grid technologies can accelerate transmission grids expansion by 5 to 8 years and distribution grids expansion by 4 to 7 years. Installing IGTs could contribute to the need for network buildout and achieve g

INTRESO Highlights Sustainable Alternatives as EU Considers a Ban on Sulfuryl Fluoride20.6.2024 08:00:00 CEST | Press release

International Treatment Solutions (INTRESO) Group has written to the EU Commission’s Standing Committee on Biocidal Products to highlight the availability of safe, effective and environmentally sustainable alternatives to sulfuryl fluoride, ahead of a 21 June meeting which will consider a ban of the chemical for the preservation treatment of wood [PT8], and as an insecticide and acaricide for the control of insects and arachnids [PT18]. On 21 June, representatives from EU Member States will vote on a proposal to ban the use of sulfuryl fluoride, an extremely harmful synthetic greenhouse gas with a global warming potential more than 4500 times that of carbon dioxide, for these fumigation purposes. In what amounts to an effective ban, the EU is considering withdrawing approvals for the continued biocidal use of sulfuryl fluoride, due to a lack of data on the potential risks to human health posed by the chemical. INTRESO Group produces BLUEFUME™, a highly effective and environmentally sus

GIST Impact, a leading impact data and analytics provider, receives investment from UBS Next20.6.2024 08:00:00 CEST | Press release

Today GIST Impact, the leading provider of impact data and analytics, announced an investment from UBS Next, the leading universal Swiss bank’s venture and innovation unit. GIST Impact delivers actionable impact intelligence to companies and investors, helping them easily measure their environmental and social impacts. The firm’s data and software are founded on a science-based, location-specific and standards-aligned approach, drawing on over 16 years of experience measuring and valuing impact. Its clients include some of the world’s largest banks, sovereign wealth funds, and technology firms. The provision of better impact data is critical in developing greater transparency for investors to help them manage their portfolios. New regulations and standards have also set a higher bar for measuring impact across value chains - whether through assessing impact materiality as part of the Corporate Sustainability Reporting Directive (CSRD) or evaluating natural capital impact as part of the

Grid Dynamics Wins Two MACH Impact Awards for Best Retail Project and Best Overall Change Project19.6.2024 22:05:00 CEST | Press release

Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and advanced analytics services, proudly announces that it has been awarded MACH Impact Awards for Best Retail Project and Best Overall Change Project at the MACH THREE conference, held in New York City on June 17-18, 2024. This annual conference of the MACH Alliance is home of the MACH Impact Awards, honoring MACH (Microservices, API-first, Cloud-native, and Headless) strategies and implementations that solve technical challenges and create rapid return-on-investment. Grid Dynamics’ recognition in two categories is a reflection of its co-innovation with long-time client and global footwear brand, Clarks. The awards highlight Grid Dynamics’ exceptional ability to help clients craft innovative MACH-based solutions that create substantial business impact. “To have the most significant and challenging digital modernisation Clarks has ever undertak

Verimatrix XTD Dashboard Evolves: Revolutionizing Risk Visibility, Tracking, and Actionability19.6.2024 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced major enhancements to its XTD dashboard, providing customers with greater visibility into application security risks and more actionable insights to better protect mobile apps and users. First launched in early 2022, the updated XTD dashboard introduces an all new risk classification model that replaces numerical scores with four clear implication classifications -- Informational, Low, Suspicious and High. This allows security teams to quickly understand the severity and context around detected threats. Detailed explanations accompany each risk level, ensuring transparency. In addition to the new risk scoring model, the XTD dashboard provides specific remediation guidance mapped to each risk level. Teams can immediately see recommended steps for investigating, applying protections or addressing vulnerabilities based on the evaluated threat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye